NO20090334L - DHA-estere og anvendelse derav i behandling og forebygging av kordiovaskulaer sykdom - Google Patents

DHA-estere og anvendelse derav i behandling og forebygging av kordiovaskulaer sykdom

Info

Publication number: NO20090334L
Authority: NO; Norway
Prior art keywords: following formula; cardiovascular disease; treating; same; preventing cardiovascular
Prior art date: 2006-06-23

Application number

NO20090334A

Other languages

English (en)

Norwegian (no)

Inventor

Jean Gardette

Jean-Francois Patoiseau

Andre Delhon

Frederique Brune

Alain Marty

Etienne Severac

Original Assignee

Pf Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-23

Filing date

2009-01-21

Publication date

2009-03-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090334(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-01-21 Application filed by Pf Medicament filed Critical Pf Medicament

2009-03-04 Publication of NO20090334L publication Critical patent/NO20090334L/no

Links

208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 abstract 1
206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 abstract 1
KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 abstract 1
229940090949 docosahexaenoic acid Drugs 0.000 abstract 1
MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract 1
235000020669 docosahexaenoic acid Nutrition 0.000 abstract 1
-1 docosahexaenoic acid ester Chemical class 0.000 abstract 1
229960000367 inositol Drugs 0.000 abstract 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 abstract 1
229960002479 isosorbide Drugs 0.000 abstract 1
229960003827 isosorbide mononitrate Drugs 0.000 abstract 1
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229960004738 nicotinyl alcohol Drugs 0.000 abstract 1
229940101267 panthenol Drugs 0.000 abstract 1
235000020957 pantothenol Nutrition 0.000 abstract 1
239000011619 pantothenol Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 abstract 1
235000019156 vitamin B Nutrition 0.000 abstract 1
239000011720 vitamin B Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/02—Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Cardiology (AREA)
Public Health (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20090334A 2006-06-23 2009-01-21 DHA-estere og anvendelse derav i behandling og forebygging av kordiovaskulaer sykdom NO20090334L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0605649A FR2902659A1 (fr)	2006-06-23	2006-06-23	Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
PCT/EP2007/056277 WO2007147899A2 (fr)	2006-06-23	2007-06-22	Esters de dha et leur utilisation dans le traitement et la prévention d'une maladie cardiovasculaire

Publications (1)

Publication Number	Publication Date
NO20090334L true NO20090334L (no)	2009-03-04

Family

ID=37686083

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20090334A NO20090334L (no)	2006-06-23	2009-01-21	DHA-estere og anvendelse derav i behandling og forebygging av kordiovaskulaer sykdom

Country Status (38)

Country	Link
US (2)	US8034377B2 (fr)
EP (1)	EP2034999B9 (fr)
JP (1)	JP5053372B2 (fr)
KR (1)	KR101380128B1 (fr)
CN (1)	CN101472590A (fr)
AR (1)	AR061622A1 (fr)
AT (1)	ATE489091T1 (fr)
AU (1)	AU2007262958B2 (fr)
BR (1)	BRPI0713725A2 (fr)
CA (1)	CA2655570C (fr)
CL (1)	CL2010001123A1 (fr)
CO (1)	CO6150156A2 (fr)
CR (1)	CR10507A (fr)
DE (1)	DE602007010776D1 (fr)
DK (1)	DK2034999T3 (fr)
EC (1)	ECSP099039A (fr)
ES (1)	ES2355611T3 (fr)
FR (1)	FR2902659A1 (fr)
GE (1)	GEP20125464B (fr)
HN (1)	HN2008001771A (fr)
HR (1)	HRP20110086T1 (fr)
IL (1)	IL195562A (fr)
MA (1)	MA30584B1 (fr)
MX (1)	MX2009000103A (fr)
MY (1)	MY145985A (fr)
NO (1)	NO20090334L (fr)
NZ (1)	NZ573454A (fr)
PL (1)	PL2034999T3 (fr)
PT (1)	PT2034999E (fr)
RS (1)	RS51629B (fr)
RU (1)	RU2451672C2 (fr)
SA (1)	SA07280345B1 (fr)
SI (1)	SI2034999T1 (fr)
TN (1)	TNSN08527A1 (fr)
TW (1)	TWI389888B (fr)
UA (1)	UA96156C2 (fr)
WO (1)	WO2007147899A2 (fr)
ZA (1)	ZA200900334B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2334536B1 (es) *	2008-04-11	2011-01-24	Universidad Complutense De Madrid	Procedimiento para la obtencion selectiva de 12-hidroxi-9-cis-octadecenoato de (1,4:3,6-dianhidro-d-glucitol) utilizando lipasas inmovilizadas como catalizador.
FR2949063B1 (fr) *	2009-08-11	2011-09-30	Pf Medicament	Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
CN102946904A (zh)	2010-06-18	2013-02-27	埃克斯生物科技公司	关节炎治疗
FR2963790B1 (fr) *	2010-08-11	2012-09-28	Pf Medicament	Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
PH12013500316A1 (en)	2010-08-23	2016-09-02	Janssen Biotech Inc	Treatment for neoplastic diseases
US9724409B2 (en)	2011-04-01	2017-08-08	Xbiotech, Inc.	Treatment of inflammatory skin disease
CN102757444B (zh) *	2011-04-29	2016-02-10	南京信诺泰医药有限公司	具有一氧化氮供体性质的苯并呋喃类化合物
FR2998479B1 (fr) *	2012-11-27	2017-04-28	Pf Medicament	Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
WO2016024283A1 (fr) *	2014-08-12	2016-02-18	Praj Industries Limited	Procédé pour la préparation de triglycérides de l'epa et du dha
US10441087B2 (en)	2015-02-24	2019-10-15	Sleep Number Corporation	Mattress with adjustable firmness
JP7145162B2 (ja)	2017-02-16	2022-09-30	ヤンセンバイオテク，インコーポレイテッド	化膿性汗腺炎の処置
IL268804B2 (en) *	2017-02-20	2023-04-01	Univ Louisiana State	Hydrogen sulfide and/or nitrite for the treatment and prevention of atrial fibrillation
CN110950881A (zh) *	2018-09-27	2020-04-03	中国科学院上海药物研究所	一类三环类似物、其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL133049C (fr)	1966-02-24
JPS5967263A (ja)	1982-10-07	1984-04-16	Terumo Corp	ペンタエン高級脂肪酸ピリジルアルコ−ルエステルおよびその製法
JPS5967264A (ja)	1982-10-08	1984-04-16	Terumo Corp	血小板凝集抑制剤
EP0125252A1 (fr) *	1982-11-16	1984-11-21	MOTSCHAN, Georges	Nouvelle utilisation d'une vitamine unique ou d'une combinaison de diverses vitamines
JPS6034947A (ja) *	1983-08-05	1985-02-22	Terumo Corp	ドコサヘキサエン酸誘導体およびそれを用いた血小板凝集阻止剤
GB9300125D0 (en) *	1993-01-06	1993-03-03	Scotia Holdings Plc	Compositions containing esters of unsaturated fatty acids
US5760081A (en) *	1994-05-10	1998-06-02	The General Hospital Corporation	Omega 3 fatty acids in the prevention of ventricular fibrillation
CA2220091C (fr)	1995-05-01	2011-01-04	Scotia Holdings Plc	Esters d'acide nicotinique et compositions pharmaceutiques contenant de tels esters
IL118092A0 (en)	1995-05-03	1996-09-12	Smithkline Beecham Plc	Antibacterial compounds their preparation and pharmaceutical compositions containing them
US5919815A (en) *	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
US5795909A (en)	1996-05-22	1998-08-18	Neuromedica, Inc.	DHA-pharmaceutical agent conjugates of taxanes
AUPQ480399A0 (en)	1999-12-22	2000-02-03	Commonwealth Scientific And Industrial Research Organisation	Unsaturated fatty acids and their uses in therapy
EP1157692B1 (fr)	2000-05-22	2005-10-05	Pro Aparts - Investimentos E Consultoria Lda	Composition pharmaceutique d'acides gras, contenant au moins 80% en poids de EPA et DHA
ITMI20010129A1 (it) *	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US7704542B2 (en) *	2001-09-12	2010-04-27	Xanodyne Pharmaceuticals, Inc.	Vitamin/mineral compositions with DHA
US8729124B2 (en) *	2002-03-05	2014-05-20	Pronova Biopharma Norge As	Use of EPA and DHA in secondary prevention
ITMI20022511A1 (it) *	2002-11-26	2004-05-27	Victorix Assets Ltd	Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
EP1466597A1 (fr) *	2003-04-07	2004-10-13	Clinigenetics	Usage d'estères du dha pour le traitement des maladies vasculaires
WO2004091603A1 (fr) *	2003-04-07	2004-10-28	Clinigenetics	Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
JP2006523642A (ja)	2003-04-17	2006-10-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	妊娠女性用のマルチ−ビタミンおよびミネラル補助剤

2006
- 2006-06-23 FR FR0605649A patent/FR2902659A1/fr active Pending
2007
- 2007-06-22 MY MYPI20084785A patent/MY145985A/en unknown
- 2007-06-22 BR BRPI0713725-7A patent/BRPI0713725A2/pt not_active IP Right Cessation
- 2007-06-22 CN CNA2007800228209A patent/CN101472590A/zh active Pending
- 2007-06-22 AU AU2007262958A patent/AU2007262958B2/en not_active Ceased
- 2007-06-22 HR HR20110086T patent/HRP20110086T1/hr unknown
- 2007-06-22 NZ NZ573454A patent/NZ573454A/en not_active IP Right Cessation
- 2007-06-22 EP EP07765584A patent/EP2034999B9/fr active Active
- 2007-06-22 RS RS20110091A patent/RS51629B/sr unknown
- 2007-06-22 PL PL07765584T patent/PL2034999T3/pl unknown
- 2007-06-22 AT AT07765584T patent/ATE489091T1/de active
- 2007-06-22 JP JP2009517144A patent/JP5053372B2/ja not_active Expired - Fee Related
- 2007-06-22 RU RU2008152248/04A patent/RU2451672C2/ru not_active IP Right Cessation
- 2007-06-22 MX MX2009000103A patent/MX2009000103A/es active IP Right Grant
- 2007-06-22 UA UAA200900468A patent/UA96156C2/ru unknown
- 2007-06-22 DE DE602007010776T patent/DE602007010776D1/de active Active
- 2007-06-22 CA CA2655570A patent/CA2655570C/fr not_active Expired - Fee Related
- 2007-06-22 DK DK07765584.3T patent/DK2034999T3/da active
- 2007-06-22 AR ARP070102779A patent/AR061622A1/es not_active Application Discontinuation
- 2007-06-22 WO PCT/EP2007/056277 patent/WO2007147899A2/fr not_active Ceased
- 2007-06-22 SI SI200730469T patent/SI2034999T1/sl unknown
- 2007-06-22 US US12/305,162 patent/US8034377B2/en not_active Expired - Fee Related
- 2007-06-22 KR KR1020097001053A patent/KR101380128B1/ko not_active Expired - Fee Related
- 2007-06-22 PT PT07765584T patent/PT2034999E/pt unknown
- 2007-06-22 GE GEAP200711074A patent/GEP20125464B/en unknown
- 2007-06-22 ES ES07765584T patent/ES2355611T3/es active Active
- 2007-06-22 TW TW096122472A patent/TWI389888B/zh not_active IP Right Cessation
- 2007-06-23 SA SA07280345A patent/SA07280345B1/ar unknown
2008
- 2008-11-27 HN HN2008001771A patent/HN2008001771A/es unknown
- 2008-11-27 IL IL195562A patent/IL195562A/en active IP Right Grant
- 2008-12-12 CR CR10507A patent/CR10507A/es unknown
- 2008-12-19 TN TNP2008000527A patent/TNSN08527A1/en unknown
2009
- 2009-01-07 EC EC2009009039A patent/ECSP099039A/es unknown
- 2009-01-09 MA MA31561A patent/MA30584B1/fr unknown
- 2009-01-15 ZA ZA2009/00334A patent/ZA200900334B/en unknown
- 2009-01-21 NO NO20090334A patent/NO20090334L/no not_active Application Discontinuation
- 2009-01-22 CO CO09005510A patent/CO6150156A2/es unknown
2010
- 2010-10-13 CL CL2010001123A patent/CL2010001123A1/es unknown
2011
- 2011-06-13 US US13/159,022 patent/US8227479B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2007147899A3 (fr)	2008-03-13
KR101380128B1 (ko)	2014-04-11
PT2034999E (pt)	2011-01-19
PL2034999T3 (pl)	2011-05-31
TWI389888B (zh)	2013-03-21
MY145985A (en)	2012-05-31
ES2355611T3 (es)	2011-03-29
SI2034999T1 (sl)	2011-02-28
GEP20125464B (en)	2012-04-10
SA07280345B1 (ar)	2011-01-15
MX2009000103A (es)	2009-01-23
CR10507A (es)	2009-02-05
RU2008152248A (ru)	2010-07-27
HN2008001771A (es)	2011-01-24
ATE489091T1 (de)	2010-12-15
EP2034999B1 (fr)	2010-11-24
RS51629B (sr)	2011-08-31
TW200811108A (en)	2008-03-01
WO2007147899A2 (fr)	2007-12-27
DE602007010776D1 (de)	2011-01-05
ECSP099039A (es)	2009-02-27
EP2034999A2 (fr)	2009-03-18
JP5053372B2 (ja)	2012-10-17
AU2007262958A1 (en)	2007-12-27
EP2034999B9 (fr)	2011-03-09
CA2655570C (fr)	2015-09-08
US8034377B2 (en)	2011-10-11
AU2007262958B2 (en)	2011-10-27
CA2655570A1 (fr)	2007-12-27
KR20090024794A (ko)	2009-03-09
DK2034999T3 (da)	2011-01-24
ZA200900334B (en)	2009-12-30
MA30584B1 (fr)	2009-07-01
US20090312354A1 (en)	2009-12-17
TNSN08527A1 (en)	2010-04-14
CO6150156A2 (es)	2010-04-20
BRPI0713725A2 (pt)	2012-10-30
CL2010001123A1 (es)	2011-03-25
IL195562A0 (en)	2009-09-01
AR061622A1 (es)	2008-09-10
IL195562A (en)	2012-06-28
CN101472590A (zh)	2009-07-01
HRP20110086T1 (hr)	2011-03-31
FR2902659A1 (fr)	2007-12-28
WO2007147899B1 (fr)	2008-05-02
JP2009544576A (ja)	2009-12-17
RU2451672C2 (ru)	2012-05-27
UA96156C2 (ru)	2011-10-10
NZ573454A (en)	2010-10-29
US20110237613A1 (en)	2011-09-29
US8227479B2 (en)	2012-07-24

Legal Events

Date	Code	Title	Description
2018-04-16	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
MY145985A (en)	2012-05-31	Dha esters and use thereof in treatment and prevention of cardiovascular disease
MX378496B (es)	2025-03-11	Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
CY1123945T1 (el)	2021-10-29	Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες
SG10201400685SA (en)	2015-01-29	Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
WO2009091538A3 (fr)	2009-09-24	Composition pharmaceutique et méthode permettant de traiter l'hypertriglycéridemie et l'hypercholestérolémie chez des mammifères
BR112012006692B8 (pt)	2021-05-25	composição farmacêutica compreendendo um derivado de hidróxi de atorvastatina e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato
NZ734905A (en)	2019-05-31	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AR075423A1 (es)	2011-03-30	Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
NZ618734A (en)	2015-01-30	Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
UA109252C2 (uk)	2015-08-10	Сірковмісні ліпіди для застосування як харчових добавок або медикаментів
WO2007128086A3 (fr)	2008-01-24	Nouvel inhibiteur de la réplication virale
AU2016219643A1 (en)	2016-09-15	Pharmaceutical combination for the treatment of pain
NO20074318L (no)	2007-10-24	Anvendelse av en fettsyresammensetning som inneholder DHA for fremstilling av et medisinsk produkt eller et naeringsmiddel for behandling av amyloidoserelaterte sykdommer
MX2008013017A (es)	2008-11-27	Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
MA31094B1 (fr)	2010-01-04	Utilisation de dérivés de pyranone-acide substituée pour le traitement du syndrome métabolique
WO2010028173A3 (fr)	2010-11-04	Procédé de traitement de fibrillation auriculaire
WO2009097228A3 (fr)	2009-10-15	Composition et procédé de traitement et de prévention de troubles musculosquelettiques et de tissu conjonctif
WO2009099553A3 (fr)	2009-12-30	Utilisation d’inhibiteur de kinase pour le traitement de l’athérosclérose
AR059927A1 (es)	2008-05-07	Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas
NO20084478L (no)	2008-10-23	Konjugerte lipidderivater
NO20092763L (no)	2009-07-27	Isosorbid mononitrat derivater for behandling av tarmlidelser
NO20083307L (no)	2008-07-25	Anvendelse av et ikke-forsapbart ekstrakt fra plantemasse ved behandling av hudaldring
WO2010047559A2 (fr)	2010-04-29	Formulations pharmaceutiques a liberation prolongee
NO20076426L (no)	2008-02-08	Aktiv sammensetning for behandling eller for a unnga problemer relatert til forstyrrelse av den biologiske klokken
WO2009015447A3 (fr)	2009-11-19	Nouvelle stratégie immunothérapeutique